MONTREAL, CANADA--(Marketwire - January 09, 2009) - Theratechnologies (TSX: TH) announced today the departure of Dr. Pierre Caudrelier, as Chief Medical Officer, effective immediately, to pursue other career opportunities.
Dr. Caudrelier joined Theratechnologies in August 2007 and worked actively in the completion of the Phase 3 clinical program evaluating tesamorelin in HIV-associated lipodystrophy. Dr. Caudrelier’s responsibilities will now be assumed by Dr. Christian Marsolais, Vice President, Clinical Research and Medical Affairs, Ms. Martine Ortega, Vice President, Compliance and Regulatory Affairs, Mr. Pierre Perazzelli, Vice President, Pharmaceutical Development, and Mr. Shawn Barney, Acting Vice President, Preclinical Research with these individuals reporting directly to the President and Chief Executive Officer of Theratechnologies.
“On behalf of the Board of Directors, I would like to thank Dr. Caudrelier for his time with us and wish him continued success in his future endeavors,” said Mr. Yves Rosconi, President and CEO of Theratechnologies.
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced compound, tesamorelin, has concluded its Phase 3 clinical program for a serious metabolic disorder involving excess abdominal fat in HIV patients with lipodystrophy. The Company also has other projects at earlier stages of development.
Contacts:
Theratechnologies Inc.
Aline Vandermeer
Coordinator, IR & Communications
514-336-7800, ext. 229
communications@theratech.com
www.theratech.com
